Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.05.2022 | Clinical study

Serious adverse events with tofacitinib versus TNF inhibitors

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Tofacitinib use does not increase the risk of serious adverse events (SAEs) compared with tumour necrosis factor inhibitor (TNFi) use in Korean patients with ulcerative colitis (UC), according to findings of a study published in the Journal of Korean Medical Science. …
Literatur
Zurück zum Zitat Seo GH, et al. The Comparative Risk of Serious Adverse Events With Tofacitinib and TNF Inhibitors in Patients With Ulcerative Colitis: The Korean Experience as Revealed by a National Database Journal of Korean Medical Science 37: e123, No. 16, 25 Apr 2022. Available from: URL: http://doi.org/10.3346/jkms.2022.37.e123 Seo GH, et al. The Comparative Risk of Serious Adverse Events With Tofacitinib and TNF Inhibitors in Patients With Ulcerative Colitis: The Korean Experience as Revealed by a National Database Journal of Korean Medical Science 37: e123, No. 16, 25 Apr 2022. Available from: URL: http://​doi.​org/​10.​3346/​jkms.​2022.​37.​e123
Metadaten
Titel
Serious adverse events with tofacitinib versus TNF inhibitors
Publikationsdatum
01.05.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-14402-6

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Icotinib

Case report

Formaldehyde